Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • Persone
  • Pubblicazioni
  • Facoltà
  • Ambiti Di Ricerca
  • Attrezzature

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • Persone
  • Pubblicazioni
  • Facoltà
  • Ambiti Di Ricerca
  • Attrezzature
  1. Pubblicazioni

Actual Five-year Survival After Neoadjuvant Therapy and Resection for Localized Pancreatic Ductal Adenocarcinoma

Articolo
Data di Pubblicazione:
2026
Citazione:
Actual Five-year Survival After Neoadjuvant Therapy and Resection for Localized Pancreatic Ductal Adenocarcinoma / De Stefano, F., Belfiori, G., Wu, N.F., Allen, J.N., Crn, L.C., Clark, J.W., Arcidiacono, P.G., Ferrone, C., Hong, T.S., Tamburrino, D., Partelli, S., Qadan, M., Reni, M., Ryan, D.P., Lena, M.S., Capurso, G., Weekes, C.D., Wo, J.Y., Lillemoe, K.D., Crippa, S., et al.. - In: ANNALS OF SURGERY. - ISSN 0003-4932. - (2026), pp. 1-10. [10.1097/SLA.0000000000007214]
Abstract:
Objective: To determine actual 5-year survival after neoadjuvant therapy and resection for pancreatic ductal adenocarcinoma (PDAC). Background: Long-term outcomes after neoadjuvant therapy and resection for PDAC remain poorly defined, as current knowledge largely relies on actuarial estimates. Methods: Retrospective cohort study of consecutive patients who underwent neoadjuvant therapy followed by curative-intent pancreatectomy for localized PDAC at 2 high-volume centers between January 2015 and February 2021. Only patients with complete follow-up (death or ≥5 y) were included. The primary endpoint was actual 5-year survival from surgery. Results: Among 660 patients, actual 5-year survival was 34.5%. Recurrence occurred in 74.1% and was predominantly early, with nearly two-thirds of recurrences among patients who did not achieve 5-year survival occurring within 1 year after surgery. Long-term survivors had lower recurrence rates (92/228, 40.4%) and more commonly developed delayed (>2 y), locoregional, or pulmonary recurrence. The probability of achieving 5-year survival increased to 62.0% (95% CI: 56-67) and 81.9% (95% CI: 76-86) among patients who remained recurrence-free at 1 and 2 years, respectively. Actual 5-year survival was 42.5%, 29.0%, and 17.5% in patients with resectable, borderline-resectable, and locally advanced disease at diagnosis, respectively. Independent predictors of long-term survival included low comorbidity burden, baseline CA19-9 <200 U/mL, resectable disease at diagnosis, ypT0-1 stage, and R0 resection. Conclusions: Over one-third of patients undergoing neoadjuvant therapy and resection for localized PDAC were alive at 5 years, and most remained disease-free. Long-term outcomes were primarily determined by early systemic failure, whereas delayed oligometastatic recurrence identified a subgroup with prolonged survival.
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
De Stefano, F.; Belfiori, G.; Wu, N. F.; Allen, J. N.; Crn, L. C.; Clark, J. W.; Arcidiacono, P. G.; Ferrone, C.; Hong, T. S.; Tamburrino, D.; Partelli, S.; Qadan, M.; Reni, M.; Ryan, D. P.; Lena, M. S.; Capurso, G.; Weekes, C. D.; Wo, J. Y.; Lillemoe, K. D.; Crippa, S.; Falconi, M.; Castillo, C. F. D.
Autori di Ateneo:
ARCIDIACONO PAOLO GIORGIO
CAPURSO GABRIELE
CRIPPA STEFANO
FALCONI MASSIMO
PARTELLI STEFANO
RENI MICHELE
Link alla scheda completa:
https://iris.unisr.it/handle/20.500.11768/207696
Pubblicato in:
ANNALS OF SURGERY
Journal
  • Utilizzo dei cookie

Realizzato con VIVO | Designed by Cineca | 26.11.1.0